Comparative pharmacoeconomic analysis of the use of erythropoiesis-stimulating drugs for the treatment of anemia in cancer patients

Comparative pharmacoeconomic analysis of the use of erythropoiesis-stimulating drugs for the treatment of anemia in cancer patients

Introduction. Currently, a number of pharmacoeconomic studies describing use of erythropoietin stimulating agent (ESA) in cancer patients with anemia have been published, however, most of the publications on this topic are foreign. At the same time, there are practically no studies comparing the eco...

Full description

Bibliographic Details
Main Authors:	I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2021-12-01
Series:	Медицинский совет
Subjects:	anemia cancer patients erythropoietin alfa epoetin beta darbepoetin cost-effectiveness analysis pharmacoeconomics
Online Access:	https://www.med-sovet.pro/jour/article/view/6597

Similar Items

RATIONAL SUPPORTIVE THERAPY FOR CHEMOTHERAPY INDUCED ANEMIA: A PHARMACO-ECONOMIC ANALYSIS OF ERYTHROPOIETIN THERAPY IN CANCER PATIENTS IN RUSSIAN FEDERATION
by: V. B. Larionova, et al.
Published: (2018-07-01)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
by: Bicheng Liu, et al.
Published: (2022-06-01)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
by: Yoon S, et al.
Published: (2017-10-01)

Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis
by: Wen-Yi Li, et al.
Published: (2008-11-01)

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
by: Shubhadeep D. Sinha, et al.
Published: (2019-03-01)

Darbepoetin Use for the Treatment of Anemia in Hemodialysis Patients in Saudi Arabia
by: Shaheen Faissal, et al.
Published: (2006-01-01)

Pharmacoeconomic analysis of long term use of darbepoetin-α in treating chronic nephropathy-induced anemia in dialysed patients
by: Nicola Giotta, et al.
Published: (2007-06-01)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
by: Nan Chen, et al.
Published: (2022-03-01)

Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis
by: Paulo D. Picon, et al.
Published: (2014-08-01)

Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
by: Müzeyyen Aslaner Ak, et al.
Published: (2023-06-01)

Comparative efficacy and safety of biosimilar darbepoetin alfa in adults with anemia of chronic kidney disease
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil
by: Anna Thawanny Gadelha Moura, et al.

Recombinant erythropoietin in the treatment of anemia in cancer patients
by: S. V. Vorobiova, et al.
Published: (2022-11-01)

LONG-ACTING ERYTHROPOETIN EFFICACY IN THE TREATMENT OF NEPHROGENIC ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT A PREDIALYSIS STAGE
by: Yu S Milovanov, et al.
Published: (2012-06-01)

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model
by: Louise Crathorne, et al.
Published: (2016-02-01)

The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients
by: I. O. Dudar, et al.
Published: (2021-02-01)

USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE – CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP
by: Maria Gaydarova, et al.
Published: (2017-01-01)

Epoetin alpha in the treatment of anemia in patients with malignant solid tumors during antitumor drug therapy
by: L. Yu. Vladimirova, et al.
Published: (2022-06-01)

Own experience of treatment by epoetin-α (Eralfon®) of chemotherapy induced anemia
by: S A Bolshakova, et al.
Published: (2017-01-01)

Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trialResearch in context
by: Ping Zhang, et al.
Published: (2023-11-01)

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study
by: Mouysset JL, et al.
Published: (2016-01-01)

SEARCH OF NEW PHARMACEUTICALS ON THE BASIS OF DARBEPOETIN IN THE TREATMENT OF ISCHEMIC STROKE (REVIEW OF LITERATURE)
by: Konstantin Reznikov, et al.
Published: (2017-03-01)

CLINICAL AND ECONOMIC ANALYSIS OF USING OF LONG ACTION ERYTHROPOES STIMULATED AGENTS FOR THE TREATMENT OF ANEMIA CKD V HD PATIENTS
by: M. Kolesnyk, et al.
Published: (2015-08-01)

The use of darbepoetin alpha in infants
by: A. V. Shchegolev, et al.
Published: (2019-06-01)

Pharmacoeconomic analysis of using the darbepoetin alfa to correct anemia in patients with chronic renal failure who are on hemodialysis or peritoneal dialysis
by: I. S. Krysanov, et al.
Published: (2018-05-01)

Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study
by: Hidehiro Tabata, et al.
Published: (2019-06-01)

Chitosan and Hyaluronic Acid Nanoparticles as Vehicles of Epoetin Beta for Subconjunctival Ocular Delivery
by: Beatriz Silva, et al.
Published: (2022-02-01)

An observational study of an adjusted patient blood management protocol intended to lower rates of transfusion following total knee arthroplasty in patients with preoperative anemia
by: Hervé Hourlier, et al.
Published: (2023-12-01)

An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients
by: Besarab Anatole, et al.
Published: (2012-08-01)

Erythropoietin use and abuse
by: M Joseph John, et al.
Published: (2012-01-01)

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021-04-01)

Protective effects of Tadalafil and darbepoetin against ischemia - reperfusion injury in a rat testicular torsion model
by: Caglar Yildirim, et al.

INFLUENCE OF EPOETIN ALFA ON LEVEL OF PROINFLAMMATORY AND ANTIINFLAMMATORY CYTOKINE OF PATIENTS IN MAINTENCE HEMODIALYSIS
by: I. Dudar, et al.
Published: (2014-03-01)

Pharmacoeconomics applied to chronic hepatitis C
by: Fernando Franciosi Tatsch, et al.

Approaches to treating anemia in patients with malignancies. The 2007—2008 changes in Russian and International practice
by: N. V. Zhukov
Published: (2022-11-01)

Effect of Epoetin Alfa and Sodium Valproate in Patients with Myelodysplastic Syndrome
by: Seyed Ashkan Hosseini, et al.
Published: (2020-06-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

Effect of erythropoietin in treatment of renal anemia in a sample of Iraqi patient
by: Ali J. Hashim Al Saedi, et al.
Published: (2021-01-01)

Safety and efficacy of PDpoetin for management of anemia in patients with end stage renal disease on maintenance hemodialysis: results from a phase IV clinical trial
by: Abbas Norouzi Javidan, et al.
Published: (2014-09-01)